March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Retinitis Pigmentosa (RP) patients’ eligibility for Argus II retinal prosthesis system
Author Affiliations & Notes
  • Stanislao Rizzo
    UO Chirurgia Oftalmica, Azienda Ospedaliero-Univ Pisana, Pisa, Italy
  • Federica Genovesi Ebert
    UO Chirurgia Oftalmica, Azienda Ospedaliero-Univ Pisana, Pisa, Italy
  • Emanuele Di Bartolo
    UO Chirurgia Oftalmica, Azienda Ospedaliero-Univ Pisana, Pisa, Italy
  • Simona Murri
    UO Chirurgia Oftalmica, Azienda Ospedaliero-Univ Pisana, Pisa, Italy
  • Luca Allegrini
    UO Chirurgia Oftalmica, Azienda Ospedaliero-Univ Pisana, Pisa, Italy
  • Laura Cinelli
    UO Chirurgia Oftalmica, Azienda Ospedaliero-Univ Pisana, Pisa, Italy
  • Maura Arsiero
    Second Sight Medical Products Switzerland Sàrl EPFL-PSE A, Lausanne, Switzerland
  • Gregoire Cosendai
    Second Sight Medical Products Switzerland Sàrl EPFL-PSE A, Lausanne, Switzerland
  • Fatima Anaflous
    Second Sight Medical Products Switzerland Sàrl EPFL-PSE A, Lausanne, Switzerland
  • Argus II Study Group
    UO Chirurgia Oftalmica, Azienda Ospedaliero-Univ Pisana, Pisa, Italy
  • Footnotes
    Commercial Relationships  Stanislao Rizzo, None; Federica Genovesi Ebert, None; Emanuele Di Bartolo, None; Simona Murri, None; Luca Allegrini, None; Laura Cinelli, None; Maura Arsiero, Second Sight Medical Products Switzerland (E); Gregoire Cosendai, Second Sight Medical Products Switzerland (E); Fatima Anaflous, Second Sight Medical Products Switzerland (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 278. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Stanislao Rizzo, Federica Genovesi Ebert, Emanuele Di Bartolo, Simona Murri, Luca Allegrini, Laura Cinelli, Maura Arsiero, Gregoire Cosendai, Fatima Anaflous, Argus II Study Group; Retinitis Pigmentosa (RP) patients’ eligibility for Argus II retinal prosthesis system. Invest. Ophthalmol. Vis. Sci. 2012;53(14):278.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : We describe in detail the procedure we used for identifying the most suitable candidates to receive the Argus II retinal prosthesis system.

Methods: : In order to identify patients who could benefit the most from the Argus II epiretinal implant, we performed a screening as follows:1) First phone interview: we verified that the patients met a few basic criteria: adult (25 years old or older); severe to profound outer retinal degeneration; some residual light perception; previous history of useful form vision.We then asked if they had other associated diseases (e.g., retinal detachment, glaucoma, etc.), if they ever had ophthalmic surgery and if they suffered from Usher’s Syndrome (hearing loss associated).More general questions were then asked about their past and present school and work activities (to understand their educational level and learning speed), as well as questions about their general health status (cardio-vascular problems, neurological disorders, etc.)2) In-clinic screening: the patients pre-selected via the phone interview underwent a more comprehensive screening at the hospital: eye examination (visual acuity, intraocular tone, state of the conjunctiva, cornea, lens, presence of nystagmus, ocular motility, fundus examination), Goldmann visual field, OCT, Fluorescein Angiography, Fundus Photos, ultrasonic A-Scan, Photo Flash Test, Landolt C, Square localization, Direction of Motion, Grating Visual Acuity.Consensus within medical team members: once the first two steps of screening were completed, we reviewed all the medical and psychophysical results to assess the best candidates

Results: : From an initial list of 119 patients, all suffering from Retinitis Pigmentosa at different stages, 15 blind candidates were selected for thorough in-clinic screening. From the comparative results of these tests, 13/15 patients were found eligible to receive an Argus II implant..

Conclusions: : This is the first time we standardized a series of medical and psychophysical tests, widely accepted by the community and readily available in any eye hospital, for assessing retinal implant candidates. Results suggest that our selection process could quickly become a de facto standard in the field. Tests are fast (2h/patient), easy to perform, well tolerated by the patients, and with a clear outcome. The number of eligible patients is high with respect to to the total screened patients.

Keywords: retinal degenerations: hereditary • space and scene perception • perception 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×